It can be administered to patients with severe cases of pneumonia caused by the novel coronavirus who exhibit elevated concentrations of IL-6 and significant systemic inflammation, as indicated by elevated CRP or ferritin levels [141]. This evidence concerns the gene IL6 and susceptibility to pneumonia measurement.